ZA201402932B - Overload And Elute Chromatography - Google Patents

Overload And Elute Chromatography

Info

Publication number
ZA201402932B
ZA201402932B ZA2014/02932A ZA201402932A ZA201402932B ZA 201402932 B ZA201402932 B ZA 201402932B ZA 2014/02932 A ZA2014/02932 A ZA 2014/02932A ZA 201402932 A ZA201402932 A ZA 201402932A ZA 201402932 B ZA201402932 B ZA 201402932B
Authority
ZA
South Africa
Prior art keywords
overload
elute chromatography
elute
chromatography
Prior art date
Application number
ZA2014/02932A
Other languages
English (en)
Inventor
Nadarajah Deepa
Mehta Amit
Original Assignee
Genentech Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201402932(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware filed Critical Genentech Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Publication of ZA201402932B publication Critical patent/ZA201402932B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/14—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the introduction of the feed to the apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2014/02932A 2011-11-02 2014-04-23 Overload And Elute Chromatography ZA201402932B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554898P 2011-11-02 2011-11-02
PCT/US2012/063242 WO2013067301A1 (en) 2011-11-02 2012-11-02 Overload and elute chromatography

Publications (1)

Publication Number Publication Date
ZA201402932B true ZA201402932B (en) 2016-08-31

Family

ID=48192803

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/02932A ZA201402932B (en) 2011-11-02 2014-04-23 Overload And Elute Chromatography

Country Status (25)

Country Link
US (3) US20140301977A1 (enExample)
EP (2) EP2773438B2 (enExample)
JP (4) JP6356607B2 (enExample)
KR (1) KR20140091721A (enExample)
CN (2) CN104023804B (enExample)
AU (1) AU2012323995B2 (enExample)
BR (1) BR112014010406A2 (enExample)
CA (1) CA2854330A1 (enExample)
DK (2) DK3257564T4 (enExample)
ES (2) ES2717536T5 (enExample)
FI (1) FI3257564T4 (enExample)
HR (1) HRP20190485T4 (enExample)
HU (2) HUE035685T2 (enExample)
IL (1) IL232146A0 (enExample)
LT (1) LT3257564T (enExample)
MX (1) MX2014005330A (enExample)
PL (2) PL2773438T5 (enExample)
PT (1) PT3257564T (enExample)
RS (1) RS58472B2 (enExample)
RU (1) RU2014121884A (enExample)
SG (1) SG11201402019TA (enExample)
SI (2) SI2773438T2 (enExample)
TR (1) TR201903707T4 (enExample)
WO (1) WO2013067301A1 (enExample)
ZA (1) ZA201402932B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598223B1 (en) 2010-07-30 2022-04-06 EMD Millipore Corporation Chromatography media and method
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TR201903707T4 (tr) 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013334644B2 (en) * 2012-10-24 2018-07-12 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN110054661A (zh) 2013-12-12 2019-07-26 Emd密理博公司 使用含丙烯酰胺的过滤器分离蛋白
EP3079722B1 (en) * 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
PT3116891T (pt) 2014-03-10 2020-05-18 Richter Gedeon Nyrt Purificação de imunoglobulina utilizando passos de pré-limpeza
CN106460027B (zh) * 2014-03-24 2020-07-31 日东纺绩株式会社 使用阳离子性接枝聚合物的目标物分离浓缩方法
US10280195B2 (en) * 2014-05-28 2019-05-07 Agency For Science, Technology And Research Virus reduction method
TW201617360A (zh) 2014-06-25 2016-05-16 桂格 史考特 布蘭克 用於純化蛋白質之方法及試劑
CN104208719B (zh) * 2014-09-24 2017-05-03 北京天广实生物技术股份有限公司 一种抗体偶联药物的阳离子交换层析纯化方法
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
ES2761726T3 (es) * 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
CN106290591B (zh) * 2015-05-14 2019-07-26 上海医药工业研究院 一种庆大霉素C1a的检测方法
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
CN109716127B (zh) * 2016-08-15 2022-06-14 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
GB201702856D0 (en) * 2017-02-22 2017-04-05 Ge Healthcare Bio Sciences Ab Method in continuous chromatography
WO2019092084A1 (en) * 2017-11-08 2019-05-16 Blue Sky Vaccines Gmbh So3 chromatography for use in a method for virus purification
CN112384615A (zh) * 2018-07-04 2021-02-19 普罗拜奥根股份公司 用于纯化包膜病毒的方法
US12306152B2 (en) * 2018-12-21 2025-05-20 Solventum Intellectual Properties Company Method for testing a chromatography device used for ion exchange
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN111351876A (zh) * 2020-04-01 2020-06-30 上海中科新生命生物科技有限公司 一种抗体药中宿主细胞蛋白半绝对定量检测方法
US11379651B1 (en) * 2020-07-06 2022-07-05 Turtl Surf & Immerse Limited Methods and systems for interactive content creation
WO2022066595A1 (en) * 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
JP7620456B2 (ja) * 2021-03-15 2025-01-23 株式会社カネカ κ鎖を含む抗体の製造方法
CA3233419A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
CA3236213A1 (en) * 2021-10-27 2023-05-04 Eugene ZURLO Compositions and methods for isolating proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69732129T2 (de) * 1996-09-13 2005-12-08 Transkaryotic Therapies, Inc., Cambridge THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ
JP4031049B2 (ja) * 1996-11-27 2008-01-09 ジェネンテック，インコーポレーテッド タンパク質精製
ATE321066T1 (de) * 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20070261962A1 (en) * 2002-04-02 2007-11-15 Ryszard Gajek Separation Systems with Charge Mosaic Membrane
CN1705505B (zh) * 2002-10-18 2010-04-28 旭化成医疗株式会社 亲水微孔膜
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
KR101482791B1 (ko) * 2005-03-11 2015-01-21 와이어쓰 엘엘씨 약한 분배성 크로마토그래피법
DE112006001012B4 (de) * 2005-04-22 2017-05-18 Waters Technologies Corp. (N.D.Ges.D. Staates Delaware) Verfahren für eine auf Massenspektrometrie gerichtete Aufbereitung von Biopolymeren
ZA200900837B (en) * 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-containing proteins
BRPI0716139A2 (pt) * 2006-08-28 2013-09-17 Ares Trading Sa processo para purificaÇço de proteÍnas de fusço fc
MX2009012786A (es) 2007-06-01 2009-12-10 Hoffmann La Roche Purificacion de inmunoglobulina.
DE102009005479A1 (de) * 2009-01-21 2010-07-22 Sartorius Stedim Biotech Gmbh Vorrichtung und Verfahren für die Stofftrennung
JP5614936B2 (ja) * 2009-02-19 2014-10-29 旭化成ケミカルズ株式会社 アニオン交換基が固定された多孔膜を用いた核酸の精製方法
CN102574911B (zh) * 2009-08-07 2017-06-06 Emd密理博公司 从样品的一或多种杂质中纯化靶蛋白的方法
WO2011035282A1 (en) * 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
CN102094034A (zh) * 2009-12-09 2011-06-15 泰州新生源生物医药有限公司 一种重组人Fc融合长效干扰素的纯化工艺
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012068134A1 (en) * 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
TR201903707T4 (tr) 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.

Also Published As

Publication number Publication date
JP2018184405A (ja) 2018-11-22
HUE035685T2 (en) 2018-05-28
DK2773438T3 (en) 2017-08-21
ES2637423T3 (es) 2017-10-13
JP2022033774A (ja) 2022-03-02
PL2773438T5 (pl) 2022-01-17
SI2773438T2 (sl) 2022-05-31
US20190023768A1 (en) 2019-01-24
AU2012323995B2 (en) 2016-06-09
SG11201402019TA (en) 2014-09-26
JP6356607B2 (ja) 2018-07-11
SI2773438T1 (sl) 2017-10-30
JP6979442B2 (ja) 2021-12-15
PL3257564T5 (pl) 2024-10-07
TR201903707T4 (tr) 2019-04-22
US20140301977A1 (en) 2014-10-09
DK2773438T4 (da) 2022-01-03
RS58472B1 (sr) 2019-04-30
JP2014532718A (ja) 2014-12-08
BR112014010406A2 (pt) 2017-04-25
ES2717536T3 (es) 2019-06-21
CN107163101B (zh) 2021-08-17
CN104023804B (zh) 2017-05-24
PL3257564T3 (pl) 2019-06-28
CA2854330A1 (en) 2013-05-10
MX2014005330A (es) 2014-09-08
AU2012323995A1 (en) 2013-05-16
EP2773438A1 (en) 2014-09-10
KR20140091721A (ko) 2014-07-22
JP2020059718A (ja) 2020-04-16
US20210206836A1 (en) 2021-07-08
EP3257564B1 (en) 2019-01-23
SI3257564T1 (sl) 2019-04-30
JP7203928B2 (ja) 2023-01-13
EP3257564B2 (en) 2024-05-29
HK1201489A1 (zh) 2015-09-04
WO2013067301A1 (en) 2013-05-10
ES2637423T5 (es) 2022-03-17
EP3257564A1 (en) 2017-12-20
HRP20190485T1 (hr) 2019-04-19
EP2773438B1 (en) 2017-06-14
IL232146A0 (en) 2014-05-28
NZ624317A (en) 2016-06-24
FI3257564T4 (fi) 2024-08-30
RU2014121884A (ru) 2015-12-10
ES2717536T5 (en) 2025-02-04
PT3257564T (pt) 2019-03-22
CN107163101A (zh) 2017-09-15
EP3527274A1 (en) 2019-08-21
LT3257564T (lt) 2019-04-10
PL2773438T3 (pl) 2017-11-30
RS58472B2 (sr) 2024-10-31
HRP20190485T4 (hr) 2024-09-27
CN104023804A (zh) 2014-09-03
EP2773438A4 (en) 2015-06-03
DK3257564T3 (en) 2019-04-15
EP2773438B2 (en) 2021-10-20
HUE043755T2 (hu) 2019-09-30
SI3257564T2 (sl) 2024-10-30
DK3257564T4 (da) 2024-09-02

Similar Documents

Publication Publication Date Title
ZA201402932B (en) Overload And Elute Chromatography
GB2553727B (en) Chromatographic materials
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
SG11201404681VA (en) Chromatography media and devices
GB201020148D0 (en) Chromatography column
EP2590722A4 (en) TIMING PROCEDURE
PL2691770T3 (pl) Prekoncentrator
GB201111775D0 (en) Compounds and uses thereof
GB2478652B (en) Chromatography assembly
GB201020146D0 (en) Chromatography column
AU346758S (en) Chromatography column
EP2803993A4 (en) AUTOMATIC SAMPLER
GB201118317D0 (en) Intrathermic and interthermic extractive thermiats
AU346759S (en) Chromatography system
GB201121551D0 (en) Compounds and uses thereof
GB201121726D0 (en) Compounds and uses thereof
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
GB201108369D0 (en) Utility columns
ZA201207364B (en) Mill
AU338706S (en) Pepper mill